Renaissance Technologies LLC raised its stake in Adaptimmune Therapeutics PLC – (NASDAQ:ADAP) by 35.4% during the fourth quarter, according to its most recent 13F filing with the SEC. The fund owned 445,100 shares of the biotechnology company’s stock after buying an additional 116,400 shares during the period. Renaissance Technologies LLC owned approximately 0.63% of Adaptimmune Therapeutics PLC – worth $1,803,000 as of its most recent SEC filing.

Several other hedge funds have also modified their holdings of the company. Polar Capital LLP boosted its stake in shares of Adaptimmune Therapeutics PLC – by 20.0% in the third quarter. Polar Capital LLP now owns 60,000 shares of the biotechnology company’s stock valued at $423,000 after buying an additional 10,000 shares in the last quarter. Baker BROS. Advisors LP acquired a new stake in shares of Adaptimmune Therapeutics PLC – during the third quarter valued at about $705,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in shares of Adaptimmune Therapeutics PLC – by 7.6% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 117,234 shares of the biotechnology company’s stock valued at $826,000 after buying an additional 8,239 shares in the last quarter. 43.67% of the stock is currently owned by institutional investors and hedge funds.

Institutional Ownership by Quarter for Adaptimmune Therapeutics PLC - (NASDAQ:ADAP)

Shares of Adaptimmune Therapeutics PLC – (NASDAQ:ADAP) opened at 5.68 on Friday. The company has a 50-day moving average of $5.02 and a 200 day moving average of $4.70. The firm’s market cap is $402.12 million. Adaptimmune Therapeutics PLC – has a one year low of $3.76 and a one year high of $11.59.



Adaptimmune Therapeutics PLC – (NASDAQ:ADAP) last announced its earnings results on Monday, March 13th. The biotechnology company reported ($0.22) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.27) by $0.05. Adaptimmune Therapeutics PLC – had a negative return on equity of 31.56% and a negative net margin of 667.22%. The company had revenue of $8.54 million for the quarter, compared to analyst estimates of $3.98 million. On average, equities research analysts expect that Adaptimmune Therapeutics PLC – will post ($0.92) EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “Renaissance Technologies LLC Boosts Stake in Adaptimmune Therapeutics PLC – (ADAP)” was first posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this article on another publication, it was illegally stolen and republished in violation of US & international trademark & copyright law. The legal version of this article can be read at https://www.thecerbatgem.com/2017/04/21/renaissance-technologies-llc-boosts-stake-in-adaptimmune-therapeutics-plc-adap.html.

ADAP has been the topic of several research reports. Zacks Investment Research raised shares of Adaptimmune Therapeutics PLC – from a “hold” rating to a “buy” rating and set a $4.50 price target on the stock in a research report on Tuesday, January 10th. Wells Fargo & Co initiated coverage on shares of Adaptimmune Therapeutics PLC – in a research report on Friday, March 17th. They set a “market perform” rating on the stock. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and three have assigned a buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus target price of $11.83.

In other news, major shareholder Enterprise Associates 14 New purchased 12,870,000 shares of the company’s stock in a transaction that occurred on Monday, March 27th. The shares were acquired at an average cost of $0.70 per share, with a total value of $9,009,000.00. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, Director Orbimed Advisors Llc purchased 1,190,476 shares of the company’s stock in a transaction that occurred on Monday, March 27th. The shares were purchased at an average cost of $4.20 per share, for a total transaction of $4,999,999.20. The disclosure for this purchase can be found here.

About Adaptimmune Therapeutics PLC –

Adaptimmune Therapeutics plc is a clinical-stage biopharmaceutical company. The Company is focused on cancer immunotherapy products based on its Specific Peptide Enhanced Affinity Receptor (SPEAR) T-cell platform. The Company has developed a platform that enables it to identify cancer targets, find and genetically engineer TCR, and produce TCR therapeutic candidates for administration to patients.

5 Day Chart for NASDAQ:ADAP

Receive News & Stock Ratings for Adaptimmune Therapeutics PLC - Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptimmune Therapeutics PLC - and related stocks with our FREE daily email newsletter.